ASR Vermogensbeheer N.V. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• ASR Vermogensbeheer N.V. has acquired 8,763 shares of Alnylam Pharmaceuticals, valued at approximately $2,366,000.
• Analysts are optimistic about Alnylam Pharmaceuticals' stock, with several financial institutions increasing their price targets and a consensus rating of "Moderate Buy."
• CEO Yvonne Greenstreet sold 19,297 shares, reducing her ownership by 28.28%, while institutional investors currently own 92.97% of the company’s stock.

ASR Vermogensbeheer N.V. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 8,763 shares of the biopharmaceutical company's stock, valued at approximately $2,366,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital World Investors boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Capital Research Global Investors boosted its position in Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Alnylam Pharmaceuticals by 19.6% in the fourth quarter. Northern Trust Corp now owns 878,860 shares of the biopharmaceutical company's stock valued at $206,805,000 after acquiring an additional 143,941 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Barclays increased their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Truist Financial initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 target price on the stock. Finally, Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Four research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $403.92.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Up 1.6%

NASDAQ ALNY opened at $435.10 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $436.77. The company has a current ratio of 2.80, a quick ratio of 2.98 and a debt-to-equity ratio of 4.10. The stock's fifty day moving average price is $329.10 and its 200-day moving average price is $283.50. The stock has a market cap of $57.03 billion, a P/E ratio of -176.15 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.13) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.